BioWorld

Aug. 28, 2007

Neurochem Slides 43 Percent On Alzhemed Phase III Failure

After six months of number crunching, Neurochem Inc. confirmed what most analysts already suspected: the North American Phase III trial of Alzhemed (tramiprosate) in Alzheimer's disease did not meet its primary endpoints. (BioWorld Today) Read More

FDA Sends IDM's Junovan Back For More Trial Data

Stem Cell Transplants Give Hope For Bedside, Lessons For Bench

BioLineRx Gets BL-4040 Rights; Delves Into Acute Kidney Injury

Upstream Completes Acquisition Of Firm Focused On Parasites

Financings Roundup

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for June 3, 2026.

ASCO 2026: A revolution in pancreatic cancer

BioWorld

At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...

News in brief

BioWorld Asia

BioWorld Asia briefs for June 2, 2026

EASL 2026: Emerging liver disease targets to watch

BioWorld

At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...

Bispecific antibodies with heavy chain in green and pink, light chain in blue and yellow

ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out

BioWorld

Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...